Document:

Unassociated Document

    Exhibit
10.32

     

    INTELLECTUAL
PROPERTY SECURITY AGREEMENT

     

    This INTELLECTUAL PROPERTY
SECURITY AGREEMENT (as amended, amended and restated, supplemented or otherwise
modified from time to time, the “IP
Security Agreement”)
dated October 15, 2009, is made by AVAX TECHNOLOGIES, INC., a corporation
organized under the laws of the State of Delaware (the “Borrower”)
and AVAX INTERNATIONAL IP HOLDINGS, INC., a corporation organized under the laws
of the State of Delaware (the “IP
Sub”
and together with the Borrower, “AVAX”)
in favor of FIREBIRD GLOBAL MASTER FUND, LTD., a Cayman Islands exempted company
(the “Lender”).

     

    WHEREAS,
the Borrower has entered into a Convertible Note and Warrant Purchase Agreement,
dated as of October 15, 2009 (as amended, restated, supplemented or otherwise
modified from time to time, the “Purchase
Agreement”), together with the Lender, and has issued thereunder a
Convertible Secured Promissory Note, dated October 15, 2009 (the “Note”),
to the Lender.

     

    WHEREAS,
under the terms of the Purchase Agreement and the Note, the Borrower and the IP
Sub have each granted to the Lender a security interest in, among other
property, certain intellectual property of the Borrower and the IP Sub, and have
agreed as a condition thereof to execute this IP Security Agreement for
recording with the U.S. Patent and Trademark Office, the United States Copyright
Office and other governmental authorities.

     

    WHEREAS,
IP Sub will derive substantial benefit and advantage from the loans and other
financial accommodations to Borrower as set forth in the Purchase Agreement, and
it will be to IP Sub’s direct interest and economic benefit to assist Borrower
in procuring said loans and other financial accommodations from the
Lender.

     

    NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, each of the Borrower and the IP Sub agrees as
follows:

     

    SECTION
1.      Grant
of Security.
As security for the prompt and complete payment and performance in full of all
obligations under the Purchase Agreement and the Note, Borrower and IP Sub
hereby pledges and hereby grants to Lender, a first priority security interest
(the “Security Interest”) in, and a lien on, all of the Intellectual Property
Assets now owned or hereafter acquired by Borrower or IP Sub or in which the
Borrower or IP Sub now has or hereafter may acquire any right, title or
interest, excluding any Intellectual Property Assets to the extent that such
Intellectual Property Assets are pledged, as of the date hereof, to Cancer
Treatment Centers of America, Inc. to secure certain obligations of the Borrower
thereto (the “Collateral”).
“Intellectual Property Assets” shall mean all right, title and interest of
Borrower or IP Sub in or to all or any Intellectual Property, which is defined
as:

     

    (i)    
each and all of the patents and patent applications, owned by, issued or granted
to, filed by or hereafter issued or granted to filed by or acquired by Borrower
or IP Sub, whether or not on a joint basis with any other person or entity,
including without limitation those patents and patent applications listed in
Schedule 1 attached hereto (collectively, the “Patents”);

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (ii)  
 each and all of the trademarks, service marks, trademark applications, and
service mark applications, owned by, issued or granted to, filed by or hereafter
issued or granted to filed by or acquired by Borrower or IP Sub, whether or not
on a joint basis with any other person or entity, including without limitation
those trademark and service mark registrations and applications set forth in
Schedule 2 attached hereto (provided that no security interest shall be granted
in United States intent-to-use trademark applications to the extent that, and
solely during the period in which, the grant of a security interest therein
would impair the validity or enforceability of such intent-to-use trademark
applications under applicable federal law), together with the goodwill
symbolized thereby (the “Trademarks”);

     

    (iii)   each
and all of the copyrights, copyright applications and exclusive copyright
licenses, owned by, issued or granted to, filed by or hereafter issued or
granted to filed by or acquired by Borrower or IP Sub, whether or not on a joint
basis with any other person or entity, including without limitation those
copyright registrations and applications and exclusive copyright licenses set
forth in Schedule 3 attached hereto (the “Copyrights”);

     

    (iv)  
all rights to sue for past, present and future infringements of any and all of
the Patents, Trademarks and Copyrights;

     

    (v)   
all proceeds, including without limitation license royalties and proceeds of
infringement suits, based on or relating to any or all of the Patents,
Trademarks and Copyrights;

     

    (vi)  
all licenses and other agreements under which Borrower or IP Sub is licensor,
and all fees, rents, royalties, proceeds or monies thereunder, based on or
relating to any or all of the Patents, Trademarks and Copyrights, and the use
thereof;

     

    (vii) 
all rights granted to Borrower or IP Sub under a license or other agreement
pertaining to any and all patent, trademark or copyright rights of any third
party;

     

    (viii) all
formulae, processes, compounds, methods, know-how, and trade secrets relating to
the manufacture of Borrower’s or IP Sub’s products under, utilizing, or in
connection with, any or all of the Patents, Trademarks and Copyrights;
and

     

    (ix)  
all products and proceeds of the foregoing, in any form, including without
limitation insurance proceeds and all claims against third parties for loss or
damage to or destruction of any or all of the foregoing.

     

    SECTION
2.       Security
for Obligations.
The grant of a security interest in, the Collateral by the Borrower or the IP
Sub under this IP Security Agreement secures the payment or performance, as the
case may be, of all obligations of the Borrower now or hereafter existing under
or in respect of the Purchase Agreement and the Note, whether direct or
indirect, absolute or contingent, and whether for principal, reimbursement
obligations, interest, premiums, penalties, fees, indemnifications, contract
causes of action, costs, expenses or otherwise (together, the “Obligations”).

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    SECTION
3.       Recordation.
The Borrower and the IP Sub each hereby authorizes and requests that the
Register of Copyrights, the Commissioner for Patents and the Commissioner for
Trademarks and any other applicable government officer record this IP Security
Agreement.

     

    SECTION
4.        Representations
and Warranties.
The Borrower and the IP Sub jointly and severally represent and warrant, as of
the date hereof, to the Lender that:

     

    (a)             
The Borrower or the IP Sub has good and valid rights in and title to the
Collateral with respect to which they have purported to grant a security
interest hereunder and has full power and authority to grant to the Lender the
security interest in such Collateral pursuant hereto and to execute, deliver and
perform its obligations in accordance with the terms of this IP Security
Agreement, without the consent or approval of any other person other than any
consent or approval that has been obtained and is in full force and
effect.

     

    (b)             
The security interest constitutes (i) a legal and valid security interest in all
the Collateral securing the payment and performance of the Obligations, (ii) a
perfected security interest in all Collateral in which a security interest may
be perfected by filing, recording or registering a financing statement or
analogous document in the in the United States of America, its territories or
possessions, any constituent State of the United States of America or the
District of Columbia pursuant to the Uniform Commercial Code or other applicable
law in such jurisdictions and (iii) a security interest that shall be perfected
in all Collateral in which a security interest may be perfected upon the receipt
and recording of this IP Security Agreement with the United States Patent and
Trademark Office and the United States Copyright Office, as applicable. The
security interest is and shall be prior to any other lien on any of the
Collateral.

     

    (c)             
The Collateral is owned by the Borrower or the IP Sub free and clear of any lien
or other security interest. The Borrower and the IP Sub have not filed or
consented to the filing of (i) any financing statement or analogous document
under the Uniform Commercial Code or any other applicable laws covering any
Collateral, (ii) any assignment in which the Borrower or the IP Sub assigns any
Collateral or any security agreement or similar instrument covering any
Collateral with the United States Patent and Trademark Office or the United
States Copyright Office, (iii) any notice under the Assignment of Claims Act or
(iv) any assignment in which the Borrower or the IP Sub assigns any Collateral
or any security agreement or similar instrument covering any Collateral with any
foreign governmental, municipal or other office, which financing statement or
analogous document, assignment, security agreement or similar instrument is
still in effect.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    SECTION
5.       Covenants.
The Borrower and the IP Sub hereby jointly and severally covenant that each of
them will:

     

    (a)    
          Notify the Lender
promptly in writing of any change (i) in the Borrower’s or the IP Sub’s legal
name, as reflected in its organizational documents, (ii) in the jurisdiction of
organization or formation of the Borrower or the IP Sub, (iii) if it is not a
registered organization (as defined in the Uniform Commercial Code in effect
from time to time in Delaware), in the location of its chief executive office or
its principal place of business, (iv) in the Borrower’s or the IP Sub’s
organizational form or (v) in the Borrower’s or the IP Sub’s Federal Taxpayer
Identification Number or organizational identification number assigned by the
jurisdiction of organization. The Borrower and the IP Sub agree to promptly
provide the Lender with certified organizational documents reflecting any of the
changes described in the first sentence of this paragraph. The Borrower and the
IP Sub agree not to effect or permit any change referred to in the preceding
sentence unless all filings have been made under the Uniform Commercial Code or
otherwise that are required in order for the Lender to continue at all times
following such change to have a valid, legal and perfected security interest in
all the Collateral. The Borrower and the IP Sub also agrees promptly to notify
the Lender in writing if any material portion of the Collateral is damaged or
destroyed.

     

    (b)             
Maintain, at its own cost and expense, such complete and accurate records with
respect to the Collateral owned by it as is consistent with its current
practices and in accordance with such prudent and standard practices used in
industries that are the same as or similar to those in which the Borrower is
engaged, but in any event to include complete accounting records indicating all
payments and proceeds received with respect to any part of the Collateral, and,
at such time or times as the Lender may request, promptly to prepare and deliver
to the Lender a duly certified schedule or schedules in form and detail
satisfactory to the Lender showing the identity, amount and location of any and
all Collateral.

     

    (c)              
At its own expense, take any and all actions necessary to defend title to the
Collateral against all persons and to defend the security interest and the
priority thereof against any lien.

     

    (d)              At
its own expense, promptly execute, acknowledge, deliver and cause to be duly
filed all such further instruments and documents and take all such actions as
the Lender may from time to time request to better assure, obtain, preserve,
protect and perfect the security interest and the rights and remedies created
hereby, including the payment of any fees and taxes required in connection with
the execution and delivery of this IP Security Agreement, the granting of the
security interest and the filing of any financing or continuation statements
(including fixture filings) or other documents in connection herewith or
therewith. If any amount payable to the Lender under or in connection with any
of the Collateral shall be or become evidenced by any promissory note or other
instrument, such note or instrument shall be promptly pledged and delivered to
the Lender, duly endorsed in a manner satisfactory to the Lender.

     

    (e)              
Remain liable to observe and perform all the conditions and obligations to be
observed and performed by it under each contract, agreement or instrument
relating to the Collateral, all in accordance with the terms and conditions
thereof, and the Borrower and the IP Sub each agree to indemnify and hold
harmless the Lender from and against any and all liability for such
performance.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (f)              
 Not make or permit to be made an assignment, pledge or hypothecation of
the Collateral or grant any other lien in respect of the Collateral or permit
any notice to be filed under the Assignment of Claims Act. The Borrower and the
IP Sub shall not make or permit to be made any transfer of the Collateral and
the Borrower and the IP Sub shall remain at all times in possession or otherwise
in control of the Collateral owned by it.

     

    (g)             
Not, and will not permit any of its licensees to, do any act, or omit to do any
act, whereby any Patent may become invalidated or dedicated to the public, and
agrees that it shall continue to mark any products covered by a Patent with the
relevant patent number as necessary and sufficient to establish and preserve its
maximum rights under applicable patent laws.

     

    (h)              For
each Trademark, (i) maintain such Trademark in full force free from any claim of
abandonment or invalidity for non-use, (ii) maintain the quality of products and
services offered under such Trademark, (iii) display such Trademark with notice
of Federal or foreign registration to the extent necessary and sufficient to
establish and preserve its maximum rights under applicable law and (iv) not
knowingly use or knowingly permit the use of such Trademark in violation of any
third party rights.

     

    (i)               
For each work covered by a Copyright, continue to publish, reproduce, display,
adopt and distribute the work with appropriate copyright notice as necessary and
sufficient to establish and preserve its maximum rights under applicable
copyright laws.

     

    (j)              
Notify the Lender promptly if it knows or has reason to know that any
Patent, Trademark or Copyright may become abandoned, lost or dedicated to the
public, or of any material and adverse determination or development (including
the institution of, or any such determination or development in, any proceeding
in the United States Patent and Trademark Office, United States Copyright Office
or any court or similar office of any country) regarding the Borrower’s or the
IP Sub’s ownership of any Patent, Trademark or Copyright, its right to register
the same, or its right to keep and maintain the same.

     

    (k)              
Not, either itself or through any agent, employee, licensee or designee, file an
application for any Patent, Trademark or Copyright (or for the registration of
any Trademark or Copyright) with the United States Patent and Trademark Office,
United States Copyright Office or any office or agency in any political
subdivision of the United States or in any other country or any political
subdivision thereof, unless it promptly notifies the Lender, and, upon request
of the Lender, executes and delivers any and all agreements, instruments,
documents and papers as the Lender may request to evidence the security interest
in such Patent, Trademark or Copyright, and the Borrower and the IP Sub hereby
each appoint the Lender as its attorney-in-fact to execute and file such
writings for the foregoing purposes, all acts of such attorney being hereby
ratified and confirmed; such power, being coupled with an interest, is
irrevocable.

     

    (l)              
Take all necessary steps that are consistent with the practice in any proceeding
before the United States Patent and Trademark Office, United States Copyright
Office or any office or agency in any political subdivision of the United States
or in any other country or any political subdivision thereof, to maintain and
pursue each material application relating to the Patents, Trademarks and/or
Copyrights (and to obtain the relevant grant or registration) and to maintain
each issued Patent and each registration of the Trademarks and Copyrights,
including timely filings of applications for renewal, affidavits of use,
affidavits of incontestability and payment of maintenance fees, and, if
consistent with good business judgment, to initiate opposition, interference and
cancellation proceedings against third parties; provided,
however,
that the Borrower may modify or cancel any such material application relating to
each issued Patent and each registration of the Trademarks and Copyrights with
the prior written consent of the Lender that shall be given or withheld in the
Lender’s sole discretion.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (m)            
Promptly notify the Lender if the Borrower or the IP Sub knows or has reason to
believe that any Collateral consisting of a Patent, Trademark or Copyright has
been or is about to be infringed, misappropriated or diluted by a third person,
and shall, if consistent with good business judgment, promptly sue for
infringement, misappropriation or dilution and to recover any and all damages
for such infringement, misappropriation or dilution, and take such other actions
as are appropriate under the circumstances to protect such
Collateral.

     

    SECTION
6.      Execution
in Counterparts.
This IP Security Agreement may be executed in any number of counterparts, each
of which when so executed shall be deemed to be an original and all of which
taken together shall constitute one and the same agreement.

     

    SECTION
7.       Grants,
Rights and Remedies.
This IP Security Agreement has been entered into in conjunction with the
provisions of the Purchase Agreement and the Note. The Borrower and the IP Sub
do hereby acknowledge and confirm that the grant of the security interest
hereunder to, and the rights and remedies of, the Lender with respect to the
Collateral are more fully set forth in the Purchase Agreement and the Note, the
terms and provisions of which are incorporated herein by reference as if fully
set forth herein and, in the event of any conflict between this IP Security
Agreement and the Purchase Agreement or the Note, the Purchase Agreement or the
Note, as applicable, shall control.

     

    SECTION
8.        Governing
Law.
This IP Security Agreement shall be governed by, and construed in accordance
with, the laws of the State of Delaware.

     

    [SIGNATURE
PAGE FOLLOWS]

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    IN
WITNESS WHEREOF, the Borrower has caused this IP Security Agreement to be duly
executed and delivered by its officer thereunto duly authorized as of the date
first above written.

     

    
      
        
          
            
              
                
                  	 
      	
                          AVAX
      TECHNOLOGIES, INC.

                        
	 	 
	 
      	
                          By:

                        	
                          /s/
      John Prendergast

                        
	 
      	 
      	
                          Name:
      JOHN PRENDERGAST

                        
	 
      	 
      	
                          Title:  
      CHAIRMAN & CEO

                        
	 
      	 
      
	 
      	
                          Address
      for Notices:

                        
	 
      	
                          2000
      Hamilton Street

                        
	 
      	
                          Suite
      204

                        
	 
      	
                          Philadelphia,
      PA 19130

                        
	 
      	
                          Attn:
      John Prendergast

                        
	 
      	 
      
	 
      	
                          AVAX
      INTERNATIONAL IP HOLDINGS, INC.

                        
	 	 
	 
      	
                          By:

                        	
                          /s/
      John Prendergast

                        
	 
      	 
      	
                          Name:
      JOHN PRENDERGAST

                        
	 
      	 
      	
                          Title:  
      CHAIRMAN & CEO

                        
	 
      	 
      
	 
      	
                          Address
      for Notices:

                        
	 
      	
                          2000
      Hamilton Street

                        
	 
      	
                          Suite
      204

                        
	 
      	
                          Philadelphia,
      PA 19130

                        
	 
      	
                          Attn:
      John
Prendergast

                        

                

              

            

          

        

      

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      
                                        
                                          
                                            	 
      	 
      
	 
      	
                                                    FIREBIRD
      GLOBAL MASTER FUND, LTD.

                                                  
	 
      	 
      
	 
      	
                                                    By:

                                                  	
                                                    /s/
      James Passin

                                                  
	 	Name:
      James
      Passin
	 	Title:  Director
	 
      	 
      
	 
      	
                                                    Address
      for Notices:

                                                     

                                                    Firebird
      Global Master Fund, Ltd.

                                                    c/o
      Trident Trust Company (Cayman) Limited

                                                    One
      Capital Place, P.O. Box 847

                                                    George
      Town, Grand Cayman KY1-1103

                                                    Cayman
      Islands

                                                     

                                                    with
      a copy to:

                                                     

                                                    FGS
      Advisors, LLC

                                                    152
      West 57th Street, 24th Floor

                                                    New
      York, NY 10019

                                                    Attention:
      James Passin

                                                    Facsimile:
      (212)
698-9266

                                                  

                                          

                                        

                                      

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      SCHEDULE
1

       

      Patents

    

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    	 
      	 
      	
                                            Patent

                                          	 
      	 
      	 
      	
                                            Patent

                                          	 
      	 
      	 
      	 
      	 
      	 
      
	
                                            Grantor
      

                                          	 	
                                            Titles

                                          	 	
                                            Country

                                          	 	
                                            No.

                                          	 	
                                            Applic.
      No.

                                          	 	
                                            Filing
      Date

                                          	
                                             

                                          	
                                            Issue
      Date

                                          
	
                                            AVAX

                                          	 
      	
                                            Method
      for

                                          	 
      	
                                            USA

                                          	 
      	 
      	 
      	
                                            11/
      331,468;

                                          	 
      	
                                            January
      13,

                                          	 
      	 
      
	
                                            TECHNOL

                                          	 
      	
                                            producing
      a

                                          	 
      	 
      	 
      	 
      	 
      	
                                            published
      as US

                                          	 
      	
                                            2006

                                          	 
      	 
      
	
                                            OGIES,

                                          	 
      	
                                            vaccine
      for

                                          	 
      	 
      	 
      	 
      	 
      	
                                            2006/0240047

                                          	 
      	 
      	 
      	 
      
	
                                            INC.

                                          	 
      	
                                            the

                                            treatment

                                            of
      cancer

                                          	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      SCHEDULE
2

       

      Domain
Names and Trademarks

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      
        Trademark
Chart - US and International Trademarks

        Avax
Technologies, Inc.

        

        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      
                                        
                                          
                                            
                                              
                                                
                                                  
                                                    
                                                      
                                                        
                                                          
                                                            	
                                                                    Country

                                                                  	 
      	
                                                                    MARK

                                                                  	 
      	
                                                                    APP./REG.
      No.

                                                                  	 
      	
                                                                    REGISTRATION

                                                                    DATE
      OR FILING

                                                                    DATE

                                                                  	 
      	
                                                                    ACTION

                                                                  	 
      	
                                                                    DEADLINE

                                                                  	 
      	
                                                                    CLASS/GOODS

                                                                  	 
      	
                                                                    comments

                                                                  
	
                                                                    Argentina

                                                                  	 
      	
                                                                    N-VAX

                                                                  	 	
                                                                    Reg.
      No. 1860227

                                                                  	 	
                                                                    2~January-2002

                                                                  	 	First
      Renewal	 	
                                                                    2-January-2012

                                                                  	 	CLASS 5: Pharmaceutical and medicinal
      preparation for human use only; vaccines for cancer of the kidney in
      humans	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    Argentina

                                                                  	 
      	
                                                                    M-VAX

                                                                  	 
      	
                                                                    Reg.
      No. 1830547

                                                                  	 
      	
                                                                    22-May-2001

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    22-May-2011

                                                                  	 
      	
                                                                    CLASS 5: Melanoma cancer vaccines for
      human use

                                                                  	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    Argentina

                                                                  	 
      	
                                                                    P-VAX

                                                                  	 
      	
                                                                    Reg,
      No. 1860228

                                                                  	 
      	
                                                                    l-February-2002

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    1-February-2012

                                                                  	 
      	
                                                                    CLASS 5: Pharmaceutical and medicinal
      preparations; prostate cancer vaccine

                                                                  	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    Argentina

                                                                  	 
      	
                                                                    O-VAX

                                                                  	 
      	
                                                                    Reg.
      No. 1860230

                                                                  	 
      	
                                                                    l-February-2002

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    1-February-

                                                                    2012

                                                                  	 
      	
                                                                    CLASS 5: Vaccine for ovarian
      cancer

                                                                  	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    Australia

                                                                  	 
      	
                                                                    AC-VAX

                                                                  	 
      	
                                                                    Reg.
      No. 827820

                                                                  	 
      	
                                                                    17-April-2001

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    16-March-2010

                                                                  	 
      	
                                                                    CLASS 5; Pharmaceutical products and
      vaccine for the treatment of cancer

                                                                  	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    Austraiia

                                                                  	 
      	
                                                                    L-VAX

                                                                  	 
      	
                                                                    Reg.
      No. 855551

                                                                  	 
      	
                                                                    22-August-2001

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    1-November-2010

                                                                  	 
      	
                                                                    CLASS 5: Pharmaceutical products and
      vaccine for the treatment of leukemia

                                                                  	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    Australia

                                                                  	 
      	
                                                                    M-VAX

                                                                  	 
      	
                                                                    Reg.
      No. 790208

                                                                  	 
      	
                                                                    10-November-2000

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    6-April-2009

                                                                  	 
      	
                                                                    CLASS 5; Pharmaceutical products and
      vaccine for the treatment of cancer

                                                                  	 
      	
                                                                    Expired

                                                                  
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    Australia

                                                                  	 
      	
                                                                    M-VAX

                                                                  	 
      	
                                                                    Reg.
      No. 790180

                                                                  	 
      	
                                                                    10-November-2000

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    6-April-2009

                                                                  	 
      	
                                                                    CLASS 5: Pharmaceutical products and
      vaccine for the treatment of cancer

                                                                  	 
      	
                                                                    Expired

                                                                  
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    Chile

                                                                  	 
      	
                                                                    L-VAX

                                                                  	 
      	
                                                                    Reg.
      No. 631690

                                                                  	 
      	
                                                                    3-June-2002

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    3-June-2012

                                                                  	 
      	
                                                                    CLASS 5: Pharmaceutical products and
      vaccine for the treatment of leukemia

                                                                  	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    China

                                                                  	 
      	
                                                                    L-VAX

                                                                  	 
      	
                                                                    Reg.
      No. 1680429

                                                                  	 
      	
                                                                    14-December-2001

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    13-December-2011

                                                                  	 
      	
                                                                    CLASS 5: Pharmaceutical products and
      vaccine for the treatment of leukemia

                                                                  	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    China

                                                                  	 
      	
                                                                    AVAX
      & Design

                                                                  	 
      	
                                                                    Reg.
      No. 1560533

                                                                  	 
      	
                                                                    28-April-2001

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    27-April-2011

                                                                  	 
      	
                                                                    CLASS
      5: Pharmaceutical products for the treatment of
      cancer, vaccine for the treatment of cancer

                                                                  	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                                    China

                                                                  	 
      	
                                                                    N-VAX

                                                                  	 
      	
                                                                    Req.
      No. 2019490

                                                                  	 
      	
                                                                    28-January-2004

                                                                  	 
      	
                                                                    First
      Renewal

                                                                  	 
      	
                                                                    27-January-

                                                                  	 
      	CLASS 5: Pharmaceutical
    and	 
      	 
      

                                                          

                                                        

                                                      

                                                    

                                                  

                                                

                                              

                                            

                                          

                                        

                                      

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

         

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

         

        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      
                                        
                                          
                                            
                                              
                                                
                                                  
                                                    
                                                      	
                                                              COUNTRY

                                                            	 
      	
                                                              MARK

                                                            	 
      	
                                                              APP./REG.
      No.

                                                            	 
      	
                                                              REGISTRATION
DATE
      OR FILING

                                                              DATE

                                                            	 
      	
                                                              ACTION

                                                            	 
      	
                                                              DEADLINE

                                                            	 
      	
                                                              CLASS/GOODS

                                                            	 
      	
                                                              COMMENTS

                                                            
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	
                                                              2014

                                                            	 
      	
                                                              medicinal
      preparations; kidney cancer vaccine for humans

                                                            	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                              China

                                                            	 
      	
                                                              O-VAX

                                                            	 
      	
                                                              Reg.
      No. 2018825

                                                            	 
      	
                                                              28-January-2004

                                                            	 
      	
                                                              First
      Renewal

                                                            	 
      	
                                                              27-January-2014

                                                            	 
      	
                                                              CLASS 5: Pharmaceutical and medicinal
      preparations; vaccine for ovarian cancer

                                                            	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                              China

                                                            	 
      	
                                                              P-VAX

                                                            	 
      	
                                                              Reg.
      No. 2019494

                                                            	 
      	
                                                              27-January-2Q04

                                                            	 
      	
                                                              First
      Renewal

                                                            	 
      	
                                                              27-January-2014

                                                            	 
      	
                                                              CLASS 5: Pharmaceutical and medicinal
      preparations; prostate cancer vaccine

                                                            	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                              European
      Community

                                                            	 
      	
                                                              AC
      VACCINE

                                                            	 
      	
                                                              Reg.
      No. 01304021

                                                            	 
      	
                                                              12-April-2002

                                                            	 
      	
                                                              First
      Renewal

                                                            	 
      	
                                                              09-September-2009

                                                            	 
      	
                                                              CLASS 5: Vaccine for the treatment of
      cancer

                                                            	 
      	
                                                              Renewal
      Possible

                                                            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                              European
      Community

                                                            	 
      	
                                                              N-VAX

                                                            	 
      	
                                                              Reg.
      No. 01304039

                                                            	 
      	
                                                              19-January-2001

                                                            	 
      	
                                                              First
      Renewal

                                                            	 
      	
                                                              9-September-2009

                                                            	 
      	
                                                              CLASS 5: Pharmaceutical and
      medicinal preparations; kidney cancer vaccine for humans

                                                            	 
      	
                                                              
                                                                Renewal
      Possible

                                                              

                                                            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                              European
      Community

                                                            	 
      	
                                                              M-VAX

                                                            	 
      	
                                                              Reg.
      No. 01304062

                                                            	 
      	
                                                              19-January-2001

                                                            	 
      	
                                                              First
      Renewal

                                                            	 
      	
                                                              9-September-2009

                                                            	 
      	
                                                              CLASS 5: Pharmaceutical and medicinal
      preparations; melanoma cancer vaccine for humans

                                                            	 
      	
                                                              
                                                                Renewal
      Possible

                                                              

                                                            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                              European
      Community

                                                            	 
      	
                                                              P-VAX

                                                            	 
      	
                                                              Reg.
      No. 01304013

                                                            	 
      	
                                                              19-January-2001

                                                            	 
      	
                                                              First
      Renewal

                                                            	 
      	
                                                              9-September-2009

                                                            	 
      	
                                                              CLASS 5: Pharmaceutical and medicinal
      preparations; prostate cancer vaccine

                                                            	 
      	
                                                              
                                                                Renewal
      Possible

                                                              

                                                            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                              South
      Africa

                                                            	 
      	
                                                              Opposition
      to AVAX & Design

                                                            	 
      	
                                                              App.
      No. 200221365

                                                            	 
      	
                                                              27-October-2000

                                                              (Filing
      Date)

                                                              26-May-2004

                                                              (Publication,
      Date)

                                                            	 
      	 
      	 
      	
                                                               
      

                                                            	 
      	
                                                              CLASS
      5

                                                            	 
      	
                                                              This
      matter is being handled directly by Avax with local
  counsel

                                                            
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                              Japan

                                                            	 
      	
                                                              M-VAX

                                                            	 
      	
                                                              Reg.
      No. 4658803

                                                            	 
      	
                                                              4-April-2003

                                                            	 
      	
                                                              First
      Renewal

                                                            	 
      	
                                                              4-April-2013

                                                            	 
      	
                                                              CLASS 5: Melanoma cancer vaccine for
      human; other pharmaceutical and medicinal preparations

                                                            	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                              Switzerland

                                                            	 
      	
                                                              M-VAX

                                                            	 
      	
                                                              Reg.
      No. 541648

                                                            	 
      	
                                                              24-April-2006

                                                            	 
      	
                                                              First
      Renewal

                                                            	 
      	
                                                              2-December-2015

                                                            	 
      	
                                                              CLASS
      5

                                                            	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                                              US

                                                            	 
      	
                                                              AVAX
      & Design

                                                            	 
      	
                                                              Reg.
      No. 2,510,757

                                                            	 
      	
                                                              20-November-2001

                                                            	 
      	
                                                              First
      Renewal

                                                            	 
      	
                                                              20
      November-2011

                                                            	 
      	
                                                              CLASS 5: pharmaceutical preparations and
      vaccine for the treatment of cancer

                                                            	 
      	 
      

                                                    

                                                  

                                                

                                              

                                            

                                          

                                        

                                      

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

         

        
          
            
            

          

          
            2

            
              

            

          

          
            
            

          

        

         

        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    	
                                            COUNTRY

                                          	 
      	
                                            MARK

                                          	 
      	
                                            APP./REG.
      No.

                                          	 
      	
                                            REGISTRATION
DATE
      OR FILING

                                            DATE

                                          	 
      	
                                            ACTION

                                          	 
      	
                                            DEADLINE

                                          	 
      	
                                            CLASS/GOODS

                                          	 
      	
                                            COMMENTS

                                          
	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	 	 	
                                              

                                          	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                            US

                                          	 
      	
                                            MVAX

                                          	 
      	
                                            Reg.
      No. 2,929,049

                                          	 
      	
                                            l-May-2005

                                          	 
      	
                                            Declaration
      of Use/Affidavit of

                                            Incontestability

                                          	 
      	
                                            l-March-2010

                                            (Opening
      Date)

                                            1
      March - 2015

                                            (Next
      Renewal)

                                          	 
      	
                                            CLASS 5: melanoma cancer vaccine for
      humans

                                          	 
      	 
      
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
                                            US

                                          	 
      	
                                            THE
      POWER OF

                                            INDIVIDUALIZED

                                            THERAPY

                                          	 
      	
                                            Reg.
      No. 2,478,644

                                          	 
      	
                                            14-August-2001

                                          	 
      	
                                            First
      Renewal

                                          	 
      	
                                            14-August-

                                            2011

                                          	 
      	
                                            CLASS 42: Pharmaceutical research and
      cancer research services.

                                          	 
      	 
      

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

        

        
          
            
            

          

          
            3

            
              

            

          

          
            
            

          

        

      

       

      SCHEDULE
3

    

    
       

      Copyrights

       

      NONEExhibit
10.33

     

    THIS NOTE
AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS.
NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF MAY BE
TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B)
IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF
1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS. THIS NOTE IS SUBJECT TO
THAT CERTAIN CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT, DATED OCTOBER 15,
2009, BY AND AMONG AVAX AND THE PURCHASER NAMED THEREIN.

    

    AVAX
TECHNOLOGIES, INC.

    

    CONVERTIBLE
SECURED PROMISSORY NOTE

    

    
      
        	
                $1,400,000.00

              	
                                  October
      15, 2009

              

      

    

     

    AVAX
TECHNOLOGIES, INC., a Delaware corporation (“AVAX”), for value received,
promises to pay to Firebird Global Master Fund, Ltd., having an address at c/o
FGS Advisors, LLC, 152 West 57th Street, 24th Floor, New York, NY 10019 or
registered assigns (“Firebird”), the principal sum of One Million Four Hundred
Thousand Dollars ($1,400,000.00) on June 1, 2010, and interest (computed on the
basis of a 365-day year) from the date hereof on the unpaid principal amount
from time to time outstanding at the rate of six percent (6%) per annum, due and
payable in arrears on the maturity date hereof, unless payment is required at an
earlier date pursuant to the terms hereof.

     

    1.
Conversion

     

    (a) Voluntary
Conversion. At
any time after the date hereof until this Note is no longer outstanding, this
Note shall be convertible, in whole or in part, into shares of Common Stock,
$.004 par value per share, of AVAX (“Common Stock”) at the option of Firebird,
at any time and from time to time, at a rate of one (1) share of Common Stock
for each $0.01 (subject to adjustment, the “Conversion Price”) of unpaid
principal of and interest on this Note on the Conversion Date (as defined
below). Firebird shall effect conversions by delivering to AVAX a Notice of
Conversion specifying therein the principal amount of the Note to be converted
and the date on which such conversion shall be effected (such date, the
“Conversion Date”). If no Conversion Date is specified in a Notice of
Conversion, the Conversion Date shall be the date that such Notice of Conversion
is deemed delivered hereunder. Conversions hereunder shall have the effect of
lowering the outstanding principal amount of the Note in an amount equal to the
applicable conversion. Firebird and AVAX shall maintain records showing the
principal amount(s) converted and the date of such
conversion(s).

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    (b) Mandatory
Conversion. This
Note shall automatically convert into the securities described below and at the
conversion ratios described below upon the closing of the Offering (as defined
in Section 1(c)) if the closing of the Offering occurs on or prior to the
maturity date of this Note. Upon the closing of the Offering, all principal of
and accrued and unpaid interest on this Note will automatically convert, at the
election of Firebird, into either (i) 1 share of Common Stock, $.004 par value
per share, of AVAX (“Common Stock”) for each $0.01 of unpaid principal of and
interest on this Note on the conversion date, or (ii) into that number of
securities issued by AVAX in the Offering equal to the quotient obtained by
dividing the principal and accrued interest owed hereunder on the conversion
date by the lesser of (a) $.01 or (b) ninetynine percent (99%) of the price at
which the securities are issued in the Offering and otherwise on the same terms
and conditions and with the same rights and preferences as the securities issued
in the Offering. To exercise this election as to the form and amount of
securities to be received upon conversion of this Note, Firebird shall deliver
to AVAX during usual business hours at AVAX’s principal executive office written
notice in form satisfactory to AVAX that Firebird elects to receive the
conversion securities specified in either clause (i) or clause (ii) above. Such
notice shall also state the name or names (with address) in which the
certificate or certificates for shares (or other securities) that are issuable
on such conversion are to be registered.

     

    (c) Offering
of Securities. In
accordance with Section 7.3 of the Convertible Note and Warrant Purchase
Agreement dated the date hereof (the “Agreement”), AVAX will use its best
efforts to close an offering of securities on or before January 1, 2010, in
which the gross proceeds to AVAX are not less than $25,000,000 (the “Offering”).
Upon the closing of the Offering, the Note will automatically convert into
either (i) shares of Common Stock, or (ii) the securities issued in the
Offering, in accordance with Section 1(b).

     

    (d) Surrender
of Note and Delivery of Certificates. When surrendered for
automatic conversion this Note shall, unless the shares (or other securities)
issuable on conversion are to be issued in the same name as the name in which
this Note is then registered, be duly endorsed by, or accompanied by instruments
of transfer in form satisfactory to AVAX duly executed by, Firebird or his or
its duly authorized attorney. As promptly as practicable after the surrender of
this Note for conversion and the receipt of the notice specified above, AVAX
shall deliver or cause to be delivered to Firebird, or on Firebird’s written
order, a certificate or certificates for the number of full shares (or other
securities) issuable upon the conversion of this Note, in accordance with the
provisions hereof. Such conversion shall be deemed to have been made
automatically on the closing of the Offering, and from and after such time, the
holder will have no rights hereunder other than the right to receive the
conversion shares (or other securities) and Firebird in whose name any
certificate or certificates for shares of shall be issuable upon such conversion
shall be deemed to have become on the Conversion Date the holder of record of
the shares represented thereby.

     

    2. Adjustment of Conversion
Price.

     

    (a) Stock
Dividends, Stock Splits, etc. If AVAX:

     

    (i)
declares a dividend of Common Stock on its Common Stock,

     

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

     

    (ii)
subdivides its outstanding Common Stock into a larger number of shares of Common
Stock by reclassification, stock split or otherwise, or

     

    (iii)
combines its outstanding Common Stock into a smaller number of shares of Common
Stock by reclassification, reverse stock split or otherwise,

     

    the
number of shares of Common Stock issuable upon conversion of this Note pursuant
to Section 1 immediately prior to any such event shall be adjusted
proportionately so that thereafter Firebird shall be entitled to receive upon
conversion of this Note the number of shares of Common Stock which such Holder
would have owned after the happening of any of the events described above had
this Note been converted immediately prior to the happening of such event,
provided that the Conversion Price shall in no event be reduced to less than the
par value of the shares issuable upon conversion. An adjustment made pursuant to
this Section 2 will become effective immediately after the record date in the
case of a dividend and will become effective immediately after the effective
date in the case of a subdivision or combination.

     

    (b) Merger or
Consolidation.
If, prior to maturity of this Note, AVAX at any time consolidates or
merges with another corporation (other than a merger or consolidation in which
AVAX is the surviving corporation), Firebird hereof will thereafter be entitled
to receive, upon the conversion hereof, the securities or property to which a
holder of the number of shares of Common Stock then deliverable upon the
conversion hereof would have been entitled upon such consolidation or merger,
and AVAX shall take such steps in connection with such consolidation or merger
as may be necessary to ensure that the provisions hereof shall thereafter be
applicable, as nearly as reasonably may be, in relation to any securities or
property thereafter deliverable upon the conversion of this Note.

     

    (c) Subsequent
Equity Sales. (i)
If, at any time while this Note is outstanding, AVAX issues additional shares of
Common Stock or rights, warrants, options or other securities or debt
convertible, exercisable or exchangeable for shares of Common Stock or otherwise
entitling any person to acquire shares of Common Stock (collectively, “Common
Stock Equivalents”) at a price (exclusive of commissions payable by AVAX in
connection therewith) per share of Common Stock less than the Conversion Price
(as adjusted hereunder to such date), then the Conversion Price shall be reduced
to such price. For purposes of this paragraph, in connection with any issuance
of any Common Stock Equivalents, (A) the maximum number of shares of Common
Stock potentially issuable at any time upon conversion, exercise or exchange of
such Common Stock Equivalents (the “Deemed Number”) shall be deemed to be
outstanding upon issuance of such Common Stock Equivalents, (B) the Effective Price
applicable to such Common Stock shall equal the minimum dollar value of
consideration payable to AVAX to purchase such Common Stock Equivalents and to
convert, exercise or exchange them into Common Stock (net of any discounts,
fees, commissions and other expenses), divided by the Deemed Number, and (C) no
further adjustment shall be made to the Conversion Price upon the actual
issuance of Common Stock upon conversion, exercise or exchange of such Common
Stock Equivalents.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

     

    (ii)          If,
at any time while this Note is outstanding, AVAX issues Common Stock Equivalents
with an Effective Price or a number of underlying shares that floats or resets
or otherwise varies or is subject to adjustment based (directly or indirectly)
on market prices of the Common Stock (a “Floating Price Security”), then for
purposes of applying the preceding paragraph in connection with any subsequent
conversion, the Effective Price will be determined separately on each Conversion
Date and will be deemed to equal the lowest Effective Price at which any holder
of such Floating Price Security is entitled to acquire Common Stock on such
Conversion Date (regardless of whether any such holder acquires any shares on
such date).

     

    (d) Notice. If AVAX proposes to take any
action referred to in this Section 2, or to effect the liquidation, dissolution
or winding up of AVAX, then AVAX shall cause notice thereof to be mailed to
Firebird at least ten (10) days prior to the record date or effective date, as
applicable, of the stock dividend, merger, consolidation or other event subject
to this Section.

     

    (e) Statement
of Adjustment.
Whenever the Conversion Price is adjusted as provided in Section 2, AVAX
shall promptly file at its principal executive office, a statement, signed by
the Chairman of the Board, the President or any Vice President of AVAX, showing
in reasonable detail the facts requiring such adjustment and the Conversion
Price that will be effective after such adjustment. AVAX shall also cause a
notice setting forth any such adjustment to be sent by mail, first class,
postage prepaid, to Firebird. Where appropriate, such notice may be given in
advance and may be included as part of a notice required to be mailed under the
provisions of Section 2(d).

     

    (f) Fractional
Shares. No
fractional shares of Common Stock will be issued upon conversion of this Note,
but a payment in cash will be made in respect of any fraction of a share which
would otherwise be issuable upon the conversion of this Note. Such payment shall
be based on the fair market value of the Common Stock at the time of conversion
of this Note.

     

    (g) Securities
Act of 1933. Upon
conversion of this Note, Firebird may be required to execute and deliver to AVAX
an instrument, in form satisfactory to AVAX, representing that the shares (or
other securities) issuable upon conversion hereof are being acquired for
investment only and not with a view to distribution within the meaning of the
Securities Act of 1933, as amended.

     

    3. Prepayment of Principal.
The principal amount of this Note may NOT be prepaid in whole or in part,
without the prior written consent of Firebird.

     

    4.
Security.

    

    (a)          As
security for the prompt and complete payment and performance in full of all
obligations under this Note, AVAX and its subsidiary, AVAX International IP
Holdings, Inc. a Delaware corporation (the “IP Sub”), each hereby pledges and
hereby grants to Firebird, a first priority security interest (the “Security
Interest”) in, and a lien on all of the Intellectual Property Assets owned by
AVAX or by the IP Sub other than the patents rights described in that certain
License Agreement dated November 20, 1995, by and between AVAX and Thomas
Jefferson University to the extent that a prior security interest has been
granted in such patent rights to Cancer Treatment Centers of America, Inc., an
Illinois corporation. For purposes of this Note, “Intellectual Property Assets”
shall mean all right, title and interest of AVAX and the IP Sub in or to all or
any Intellectual Property, which is defined as:

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    (i)         each
and all of the patents and patent applications owned by, issued or granted to,
filed by or hereafter issued or granted to filed by or acquired by AVAX or by
the IP Sub, whether or not on a joint basis with any other person or entity,
including without limitation those patents and patent applications listed in
Schedule 1 attached hereto (collectively, the “Patents”);

    

    (ii)        all
rights to sue for past, present and future infringements of any and all of
the
Patents;

    

    (iii)       all
proceeds, including without limitation license royalties and proceeds of
infringement suits, based on or relating to any or all of the
Patents;

    

    (iv)  
    all licenses and other agreements under which AVAX or the IP
Sub is licensor, and all fees, rents, royalties, proceeds or monies thereunder,
based on or relating to any or all of the Patents and the use
thereof;

    

    (v)    
   all rights granted to AVAX or to the IP Sub under a license or
other agreement pertaining to patent rights of any third party;

    

    (vi)    
  all formulae, processes, compounds, methods, know-how, and trade
secrets relating to the manufacture of AVAX’s or the IP Sub’s products under,
utilizing, or in connection with, the Patents;

    

    (vii)      all
products and proceeds of the foregoing, in any form, including without
limitation insurance proceeds and all claims against third parties for loss or
damage to or destruction of any or all of the foregoing; and

    

    (viii)     all
other Collateral (as defined in that certain Intellectual Property Security
Agreement between and among AVAX, the IP Sub and Firebird dated October 15,
2009).

    

    (b)         Upon
either the complete voluntary or mandatory conversion of this Convertible
Secured Promissory Note by Firebird according to Section 1 such that no
principal or interest remain with respect hereto, Firebird will relinquish its
Security Interest in the Intellectual Property Assets of AVAX and of the IP
Sub.

     

    5.
Default; Remedies.

     

    (a)          The
entire unpaid principal of this Note and the interest then accrued on this Note
shall become and be immediately due and payable, upon written demand of
Firebird, or at the option of Firebird, in its sole discretion, convertible in
accordance with Section 1(a) hereof, in either case without any other notice or
demand of any kind or any presentment or protest, if any one of the following
events occurs and be continuing at the time of such demand:

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    (i)      
  If the Offering has not closed on or before the maturity date hereof
and AVAX fails to pay the principal amount of and all accrued interest on this
Note on the maturity date hereof; or

     

    (ii)     
  If AVAX defaults in the performance of any other obligation under
this Note or the Agreement, and such default continues for ten (10) days after
notice thereof by Firebird hereof to AVAX; or

     

    (iii)    
  If AVAX (i) makes an assignment for the benefit of creditors, (ii)
applies for, consents to, acquiesces in, files a petition seeking or admits (by
answer, default or otherwise) the material allegations of a petition filed
against it seeking the appointment of a trustee, receiver or liquidator, in
bankruptcy or otherwise, of itself or of all or a substantial portion of its
assets, or a reorganization, arrangement with creditors or other remedy, relief
or adjudication available to or against a bankrupt, insolvent or debtor under
any bankruptcy or insolvency law or any law affecting the rights of creditors
generally, or (iii) admits in writing its inability to pay its debts generally
as they become due; or

     

    (iv)   
  If an order for relief shall have been entered by a bankruptcy court
or if a decree, order or judgment shall have been entered adjudging AVAX
insolvent, or appointing a receiver, liquidator, custodian or trustee, in
bankruptcy or otherwise, for it or for all or a substantial portion of its
assets, or approving the winding-up or liquidation of its affairs on the grounds
of insolvency or nonpayment of debts, and such order for relief, decree, order
or judgment shall remain undischarged or unstayed for a period of sixty (60)
days; or

    

    (v)    
   If any substantial part of the property of AVAX is sequestered or
attached and is not returned to the possession of AVAX or released from such
attachment within sixty (60) days.

    

    (b)     
  Upon the occurrence and during the continuance of a default under
this section, AVAX and the IP Sub each agrees to deliver each item of Collateral
to Firebird on demand, and it is agreed that Firebird shall have the right to
take any of or all the following actions at the same or different times to the
extent permitted by applicable law: (i) on demand, to cause the security
interest to become an assignment, transfer and conveyance of any of or all
Collateral by the AVAX or by the IP Sub, as applicable, to Firebird, or to
license or sublicense, whether general, special or otherwise, and whether on an
exclusive or nonexclusive basis, any Collateral throughout the world on such
terms and conditions and in such manner as Firebird shall determine (other than
in violation of any then-existing licensing arrangements to the extent that
waivers cannot be obtained) and (ii) with or without legal process and with or
without prior notice or demand for performance, to take possession of the
Collateral and without liability for trespass to enter any premises where the
Collateral may be located for the purpose of taking possession of or removing
the Collateral and, generally, to exercise any and all rights afforded to a
secured party under the Uniform Commercial Code or other applicable law. Without
limiting the generality of the foregoing, AVAX and the IP Sub each agrees that
Firebird shall have the right to sell or otherwise dispose of all or any part of
the Collateral at a public or private sale or at any broker’s board or on any
securities exchange, for cash, upon credit or for future delivery as Firebird
shall deem appropriate. Firebird shall be authorized at any such sale (if it
deems it advisable to do so) to restrict the prospective bidders or purchasers
to persons who will represent and agree that they are purchasing the Collateral
for their own account for investment and not with a view to the distribution or
sale thereof, and upon consummation of any such sale Firebird shall have the
right to assign, transfer and deliver to the purchaser or purchasers thereof the
Collateral so sold. Each such purchaser at any such sale shall hold the property
sold absolutely, free from any claim or right on the part of AVAX or the IP Sub,
and AVAX and the IP Sub each hereby waives (to the extent permitted by law) all
rights of redemption, stay and appraisal which AVAX or the IP Sub now has or may
at any time in the future have under any rule of law or statute now existing or
hereafter enacted.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    

    Firebird
shall give AVAX or the IP Sub, as applicable, 10 days’ written notice (which
AVAX and the IP Sub each agrees is reasonable notice within the meaning of the
Uniform Commercial Code in effect from time to time in Delaware or its
equivalent in other jurisdictions) of Firebird’s intention to make any sale of
Collateral. Such notice, in the case of a public sale, shall state the time and
place for such sale and, in the case of a sale at a broker’s board or on a
securities exchange, shall state the board or exchange at which such sale is to
be made and the day on which the Collateral, or portion thereof, will first be
offered for sale at such board or exchange. Any such public sale shall be held
at such time or times within ordinary business hours and at such place or places
as Firebird may fix and state in the notice (if any) of such sale. At any such
sale, the Collateral, or portion thereof, to be sold may be sold in one lot as
an entirety or in separate parcels, as Firebird may (in its sole and absolute
discretion) determine. Firebird shall not be obligated to make any sale of any
Collateral if it shall determine not to do so, regardless of the fact that
notice of sale of such Collateral shall have been given. Firebird may, without
notice or publication, adjourn any public or private sale or cause the same to
be adjourned from time to time by announcement at the time and place fixed for
sale, and such sale may, without further notice, be made at the time and place
to which the same was so adjourned. In case any sale of all or any part of the
Collateral is made on credit or for future delivery, the Collateral so sold may
be retained by Firebird until the sale price is paid by the purchaser or
purchasers thereof, but Firebird shall not incur any liability in case any such
purchaser or purchasers shall fail to take up and pay for the Collateral so sold
and, in case of any such failure, such Collateral may be sold again upon like
notice. At any public (or private) sale made pursuant to this Agreement,
Firebird may bid for or purchase, free from any right of redemption, stay,
valuation or appraisal on the part of AVAX or the IP Sub (all said rights being
also hereby waived and released), the Collateral or any part thereof offered for
sale and may make payment on account thereof by using any claim then due and
payable to Firebird from AVAX or the IP Sub as a credit against the purchase
price, and Firebird may, upon compliance with the terms of sale, hold, retain
and dispose of such property without further accountability to AVAX or to the IP
Sub therefor. For purposes hereof, a written agreement to purchase the
Collateral or any portion thereof shall be treated as a sale thereof; Firebird
shall be free to carry out such sale pursuant to such agreement and AVAX and the
IP Sub shall not be entitled to the return of the Collateral or any portion
thereof subject thereto, notwithstanding the fact that after Firebird shall have
entered into such an agreement all defaults shall have been remedied and the
obligations hereunder paid in full. As an alternative to exercising the power of
sale herein conferred upon it, Firebird may proceed by a suit or suits at law or
in equity to foreclose under this Note and to sell the Collateral or any portion
thereof pursuant to a judgment or decree of a court or courts having competent
jurisdiction or pursuant to a proceeding by a court-appointed receiver. Any sale
pursuant to the provisions of this subsection shall be deemed to conform to the
commercially reasonable standards as provided in the Uniform Commercial Code in
effect from time to time in Delaware or its equivalent in other
jurisdictions.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    

    (c)         
Firebird shall apply the proceeds of any collection, sale, foreclosure or other
realization upon any Collateral, including any Collateral consisting of cash, in
its sole and absolute discretion. Firebird shall have sole and absolute
discretion as to the time of application of any such proceeds, moneys or
balances in accordance with this Note. Upon any sale of Collateral by Firebird
(including pursuant to a power of sale granted by statute or under a judicial
proceeding), the receipt of Firebird or of the officer making the sale shall be
a sufficient discharge to the purchaser or purchasers of the Collateral so sold
and such purchaser or purchasers shall not be obligated to see to the
application of any part of the purchase money paid over to Firebird or such
officer or be answerable in any way for the misapplication thereof.

     

    (d)        
 For the purpose of enabling Firebird to exercise rights and remedies under
this Agreement at such time as Firebird shall be lawfully entitled to exercise
such rights and remedies, AVAX and the IP Sub each hereby grants to Firebird an
irrevocable, nonexclusive license (exercisable without payment of royalty or
other compensation to AVAX or to the IP Sub), to use, license or sublicense any
of the Collateral now owned or hereafter acquired by AVAX or by the IP Sub, and
wherever the same may be located, and including in such license reasonable
access to all media in which any of the licensed items may be recorded or stored
and to all computer software and programs used for the compilation or printout
thereof. The use of such license by Firebird may be exercised, at the option of
Firebird, only upon the occurrence and during the continuation of a default;
provided, however, that
any license, sublicense or other transaction entered into by Firebird in
accordance herewith shall be binding upon AVAX and the IP Sub notwithstanding
any subsequent cure of an default.

     

    6.
General.

     

    (a) Successors
and Assigns. This
Note, and the obligations and rights of AVAX and of the IP Sub hereunder, shall
be binding upon and inure to the benefit of AVAX, the IP Sub, Firebird, and
their respective successors and assigns.

     

    (b) Recourse. Recourse under this Note is
to the assets of AVAX and the IP Sub jointly and severally (including, without
limitation, the Collateral) only and in no event to the officers, directors or
stockholders of AVAX.

     

    (c) Changes. Changes in or additions to
this Note may be made or compliance with any term, covenant, agreement,
condition or provision set forth herein may be omitted or waived (either
generally or in a particular instance and either retroactively or
prospectively), upon written consent of AVAX and Firebird.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    (d) Currency. All payments shall be made
in such coin or currency of the United States of America as at the time of
payment is legal tender therein for the payment of public and private
debts.

     

    (e) Saturdays,
Sundays, Holidays.
If any date specified in this Note as a date for the making of any
payment of principal or interest under this Note falls on a Saturday, Sunday or
on a day that is a legal holiday in the State of Pennsylvania, then the date for
the making of that payment shall be the next subsequent day that is not a
Saturday, Sunday or legal holiday.

     

    (f) Governing
Law. This Note
shall be construed and enforced in accordance with, and the rights of the
parties shall be governed by, the laws of the State of
Delaware.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    IN WITNESS WHEREOF, this Note
has been executed and delivered on the date first above written by the duly
authorized representative of AVAX.

    

    
      
        
          
            
              
                	 
      	
                        AVAX
      TECHNOLOGIES, INC.

                      
	 
      	 
      	 
      
	 
      	
                        By: 

                      	
                        /s/
      John Prendergast

                      
	 
      	 
      	
                        Name:
      John Prendergast

                      
	 
      	 
      	
                        Title:
      Chairman and CEO

                      
	 
      	 
      	 
      
	 
      	
                        AVAX
      INTERNATIONAL IP HOLDINGS, INC.

                      
	 
      	 
      	 
      
	 
      	
                        By: 

                      	
                        /s/
      John Prendergast

                      
	 
      	 
      	
                        Name:
      John Prendergast

                      
	 
      	 
      	
                        Title:
      Chairman and
CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}]]